Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06134934

TeleCare North Diabetes

This feasibility study will evaluate the feasibility of two telemonitoring designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Steno Diabetes Center North Denmark

Aalborg, 9000, Denmark

About this study

Background: Maintaining optimal glycaemic control in type 2 diabetes (T2D) is difficult. Telemedicine has potential to support poorly controlled people with T2D in the achievement of glycaemic control if the telemedicine solution includes a telemonitoring component. However, only few telemonitoring solutions for non-insulin treated T2D exist. Therefore, the aim of this feasibility study is to evaluate the feasibility of two telemonitoring intervention designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.

Method: The trial will be conducted as a three-month randomized feasibility study in four municipalities in North Denmark with 15 participants from each municipality. Two different telemonitoring intervention designs will be tested. One intervention will include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health. The second intervention will include an identical setup but with the addition of blood pressure and activity monitoring. Two municipalities will be allocated to one intervention design, whereas the other two municipalities will be allocated to the second intervention design. Qualitative interviews with participants and clinicians will be conducted to gain insight into their experiences with and acceptance of the intervention designs and trial procedures (e.g., blood sampling and questionnaires). In addition, differences in direct intervention costs between the two alternative interventions will be evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women and men ≥ 18 years
  • Poorly controlled T2D, i.e. HbA1c > 58 mmol/mol
  • Diagnosis of T2D for at least 12 months
  • General Practitioner responsible for diabetes treatment
  • Residence in Hjørring, Morsø, Jammerbugt, or Rebild municipality
  • Ability and willingness to use a smartphone/tablet along with the other devices to be used in the trial
  • Signed informed consent
  • Ability to understand and read Danish

Exclusion criteria

  • Pregnancy or breastfeeding
  • Insulin treatment
  • Prednisolone treatment
  • Severe diabetes complications such as severe neuropathy or nephropathy (dialysis treatment)
  • Participation in diabetes rehabilitation courses
  • Participation in other intervention trials
  • Terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate

Treatment and study plan

Telemonitoring 1

Other

This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.

Telemonitoring 2

Other

This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.

Primary outcomes

  1. Experiences with and acceptability of intervention design(s)

    Time frame: 3 months

    Qualitative interviews will be conducted with selected participants and HCPs to gain deeper insight into the participants and HCPs' experiences and acceptability with the two different telemonitoring intervention designs and the trial procedures.

Secondary outcomes

  1. Feasibility of the recruitment assessment 1

    Time frame: 1 month

    Number (whole) of people agreeing to receive participant information letter about the study.

  2. Feasibility of the recruitment assessment 2

    Time frame: 1 month

    Proportion (percentage) of people agreeing to receive participant information letter about the study.

  3. Feasibility of the recruitment assessment 3

    Time frame: 1 month

    Number (whole) of eligible participants who agree to participate.

  4. Feasibility of the recruitment assessment 4

    Time frame: 1 month

    Proportion (percentage) of eligible participants who agree to participate.

  5. Feasibility of the recruitment assessment 5

    Time frame: 1 month

    Potential inequalities regarding recruitment feasibility assessed by comparing those who accepted participation to those who declined with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L).

  6. Retention assessment 1

    Time frame: 3 months

    Number (whole) of participants withdrawing from the trial.

  7. Retention assessment 2

    Time frame: 3 months

    Proportion (percentage) of participants withdrawing from the trial.

  8. Retention assessment 3

    Time frame: 3 months

    Timepoint(s) for withdrawal.

  9. Retention assessment 4

    Time frame: 3 months

    Reasons of discontinuation of the trial.

  10. Retention assessment 5

    Time frame: 3 months

    Potential inequalities regarding retention feasibility assessed by comparing those who retented participation to those who withdrawal with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L).

  11. Adherence to answering the questionnaire: Diabetes-related quality of life: The Problem Areas in Diabetes Questionnaire (PAID-5)

    Time frame: At baseline (T0) and 3 months (T1)

    The respons rate for PAID-5 at baseline and at 3 months, respectively.

  12. Adherence to answering the questionnaire: Quality of Life: The Short Form 12 Questionnaire (SF-12v2)

    Time frame: At baseline (T0) and 3 months (T1)

    The respons rate for SF-12v2 at baseline and at 3 months, respectively.

  13. Adherence to answering the questionnaire: Well-being: The World Health Organization Five Well-being Index (WHO-5)

    Time frame: At baseline (T0) and 3 months (T1)

    The respons rate for WHO-5 at baseline and at 3 months, respectively.

  14. Adherence to answering the questionnaire: The Patient Activation Measure questionnaire (PAM)

    Time frame: At baseline (T0) and 3 months (T1)

    The respons rate for PAM at baseline and at 3 months, respectively.

  15. Challenges in the blood sampling schedule

    Time frame: At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)

    Explore through qualitative interviews whether there are any analysis challenges or uncertainties in the clinical workflow with regard to the blood sampling schedule.

  16. Adherence to the blood sampling schedule

    Time frame: At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)

    Number and proportion of the participants who completes the blood sampling at baseline, 3 months, 6 months, and 12 months, respectively.

  17. Costs

    Time frame: 12 months

    Differences in direct intervention costs between the two alternatives. Resource categories are comprised of equipment and time spent on monitoring, time spent training patients in using the equipment, and potential additional training for community nurses. Resources will be evaluated as prices paid and hourly wages and represented as equivalent annual costs in 2023 prices.

Sponsors and collaborators

Lead sponsor

Aalborg University Hospital

Other

Collaborators

  • Aalborg University
  • Steno Diabetes Center Nordjylland

Registry information

Official study title

TeleCare North Diabetes: A Feasibility Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Nov 18, 2023
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.